Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021156490 - CORONA VIRUS BINDERS

Publication Number WO/2021/156490
Publication Date 12.08.2021
International Application No. PCT/EP2021/052885
International Filing Date 05.02.2021
IPC
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
C07K 2317/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
22from camelids, e.g. camel, llama or dromedary
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
C07K 2317/31
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
31multispecific
Applicants
  • VIB VZW [BE]/[BE]
  • UNIVERSITEIT GENT [BE]/[BE]
  • BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US]/[US]
  • THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES [US]/[US]
  • TRUSTEES OF DARTMOUTH COLLEGE [US]/[US]
  • KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D [BE]/[BE]
  • EXEVIR BIO BV [BE]/[BE]
  • VRIJE UNIVERSITEIT BRUSSEL [BE]/[BE]
Inventors
  • SCHEPENS, Bert
  • SAELENS, Xavier
  • CALLEWAERT, Nico
  • DE VLIEGER, Dorien
  • VAN SCHIE, Loes
  • NERINCKX, Wim
  • ROOSE, Kenny
  • VAN BREEDAM, Wander
  • EECKHAUT, Hannah
  • FIJALKOWSKA, Daria
  • LONIGRO, Chiara
  • DE CAE, Sieglinde
  • DOMBRECHT, Bruno
  • STORTELERS, Catelijne
  • NEYTS, Johan
  • DELANG, Leen
  • KAPTEIN, Suzanne
  • DUARTE DA ROCHA PEREIRA, Joana
  • GRAHAM, Barney
  • MCLELLAN, Jason
  • WRAPP, Daniel
  • REMAUT, Han
Common Representative
  • VIB VZW
Priority Data
2020508.423.12.2020GB
21151356.913.01.2021EP
62/971,01306.02.2020US
62/988,61012.03.2020US
62/991,40818.03.2020US
63/041,24019.06.2020US
PCT/EP2020/07700425.09.2020EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) CORONA VIRUS BINDERS
(FR) LIANTS DU CORONAVIRUS
Abstract
(EN) The present invention relates to the field of virology, more specifically to the field of zoonotic Coronaviruses. Specifically, the invention provides for binding agents specific for the spike protein receptor binding domain (RBD) of the SARS-Corona virus, more specifically for an epitope of the RBD present in a broad range of Sarbecoviruses and mutants thereof, even more specifically present in SARS-Cov and SARS-CoV-2 viruses. More specifically, the invention relates to compositions comprising antibodies capable of specifically binding and neutralizing SARS-Corona viruses. More specifically the invention relates to compositions comprising single domain antibodies, or specifically VHHs, and compositions comprising multivalent binding agents comprising IgG Fc fusions thereof, specifically VHH-Fc fusions thereof, even more specifically comprising heavy chain only VHH72-S56A-IgG1-Fc fusions, or compositions comprising any humanized form of any one thereof, and are capable of specifically binding and neutralizing SARS-Corona viruses, specifically SARS-Cov-2 virus. The compositions are useful in the diagnosis of Sarbecoviruses, and specifically SARS-CoV-2 virus, and in prophylactic and/or therapeutic treatment of a condition resulting from infections with Sarbecoviruses, specifically SARS-Corona or SARS-CoV-2 virus, or mutants thereof.
(FR) La présente invention concerne le domaine de la virologie, plus particulièrement le domaine des coronavirus zoonotiques. Plus précisément, l'invention concerne des agents de liaison spécifiques du domaine de liaison du récepteur de la protéine de spicule (RBD) du SARS-Coronavirus, plus particulièrement un épitope du RBD présent dans une large gamme de Sarbecovirus et de leurs mutants, encore plus précisément présent dans les virus du SARS-CoV et du SARS-CoV-2. Plus particulièrement, l'invention concerne des compositions comprenant des anticorps pouvant spécifiquement se lier et neutraliser les SARS-Coronavirus. Plus précisément, l'invention concerne des compositions comprenant des anticorps à domaine unique, ou plus particulièrement des VHH, et des compositions comprenant des agents de liaison multivalents comprenant des protéines de fusion IgG-Fc associées, plus précisément des protéines de fusion VHH-Fc associées, encore plus particulièrement comprenant uniquement des protéines de fusion VHH72-S56A-IgG1-Fc à chaîne lourde uniquement, ou des compositions comprenant n'importe quelle forme humanisée de l'une quelconque des entités correspondantes, et pouvant spécifiquement se lier et neutraliser des SARS-Coronavirus, en particulier le virus du SARS-CoV-2. Les compositions sont utiles dans le diagnostic des Sarbecovirus, et spécifiquement le virus SARS-CoV-2, et dans le traitement prophylactique et/ou thérapeutique d'un état résultant d'Infections par des Sarbecovirus, spécifiquement le SARS-Coronavirus ou le virus SARS-CoV-2, ou des mutants correspondants.
Related patent documents
IL295389This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
KR1020227030791This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
EP2021712040This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau